Griffithsin Gel
The antiviral lectin Griffithsin (GRFT) has broad-spectrum activity against human immunodeficiency viruses (HIV) types 1 and 2, herpes simplex virus type 2 (HSV-2) and hepatitis C virus (HCV). The product target is a rectal microbicide gel, containing GRFT as the primary Active Pharmaceutical Ingredient (API).
Development Stage:
Preclinical – Early (Pre1)
Hormonal/Non-Hormonal:
Non-Contraceptive
Delivery Route & Method:
Topical - Gel-Rectal
Mechanism of Action:
Recombinant non-ARV live biotherapeutic product, manufactured in tobacco plants.
Developer:
- University of Louisville
Funding:
- Nat. Institute Allergy & Infect. Diseases (NIAID)
Funding Mechanism:
NIAID: U19
Active Ingredient(s):
- Griffithsin (GRFT)
Product Indication(s):
- Hepatitis
- HIV
- HSV-2